Novasep Commissions Plant Extension for Highly Potent APIs - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Novasep Commissions Plant Extension for Highly Potent APIs

PTSM: Pharmaceutical Technology Sourcing and Management
Volume 10, Issue 6

Novasep expanded its highly potent active pharmaceutical ingredients (HPAPI) manufacturing capabilities at its Le Mans facility in France; the plant extension has been fully qualified and is now being used to scale up validation of a commercial antibody-drug conjugate (ADC) payload. 
 


HPAPI, the majority of which are used in anti-cancer therapies, must be produced under strict regulatory conditions to protect any API substance from cross contamination and protect operators from the highly active properties that are intrinsic to these products. Ensuring supply chain continuity is also important to meet the rising demand in the pharmaceutical industry for ADCs.
 “There is a high demand from the pharmaceutical industry for CMOs to manufacture potent molecules for use in drugs that improve efficacy and reduce side effects," said Thierry Van Nieuwenhove, president of the Synthesis Business unit at Novasep.


The Le Mans production facility combines chemical and purification capabilities to manufacture potent and extremely potent ADC payloads at commercial scale with an occupational exposure limit lower than 30 ng/m3 at multi-kg scale per batch.
 
The production suite can also perform cryogenic chemistry at -60 °C in Hastelloy reactors.

Source: Novasep

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
29%
Oversee medical treatment of patients in the US.
11%
Provide treatment for patients globally.
7%
All of the above.
46%
No government involvement in patient treatment or drug development.
7%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
Source: PTSM: Pharmaceutical Technology Sourcing and Management,
Click here